奈达铂同步放化疗治疗老年食管癌的临床观察  

Clinical observation of NDP concurrent with radiotherapy and chemotherapy in aged patients with esophageal cancer

作　　者：王朝敏[1] 袁一枫[1] 武文娟[1] 吴志峰[1] 

机构地区：[1]江苏省苏北人民医院肿瘤内科,225009

出　　处：《中国老年保健医学》2010年第5期53-54,共2页Chinese Journal of Geriatric Care

摘　　要：目的评价单药奈达铂同步放化疗治疗老年食管癌的临床价值。方法 63例老年食管癌患者随机分为两组,试验组(奈达铂+放疗)33例,对照组(单用放疗)30例。两组放疗均采用电子直线加速器6MV-X线外照射,用模拟机定位,设三或四野,总剂量60～70GY。试验组化疗在放疗第1天开始,奈达铂(捷百舒)20mg/d,1～7d,3周为1疗程,共2疗程。结果试验组完全缓解(CR)18例,占54.5%,部分缓解(PR)12例,占36.4%,缓解病例30例,占90.1%,对照组完全缓解(CR)12例,占40.0%,部分缓解(PR)8例,占26.7%,缓解病例20例,占66.7%,两组缓解率相比P<0.01。1年和2年生存率试验组和对照组分别为84.9%,63.3%和63.6%,43.3%,二者相比较有统计学意义(P<0.01)。结论奈达铂+放疗治疗老年食管癌对缓解症状、提高生存率在临床有一定的价值。Objective To assess the clinical value of NDP concurrent with radiotherapy and chemotherapy in aged patients with esophageal cancer.Methods 63 cases with esophageal cancer were randomly divided into two groups：concurrent radiotherapy with NDP（the trial group,n=33）and simply use radiotherapy（the control group,n=30）,patients in both groups received conventional radiotherapy using electronic llinac 6MV X-ray with a total dose of 60-70Gy,simutator was used for location,three or four fields were planned,chemotherapy regime was delivered on the first day of radiotherapy,the chemotherapy in the trial group consisted of 2 cycles of NDP at 20mg oneday,1 to 7days,every 3 weeks.Results Among 33 patients in the trial group,18 achieved CR（54.5%）,12 PR（36.4%）,and respond rate（CR plus PR）was 90.1%,compared with 30 patients in the control group,12 achieved CR（40.0%）,8 PR（26.7%）,and respond rate（CR plus PR）was 66.7%,respectively（P〈0.01）,the 1-year and 2-years survival rate were 84.9% and 63.3% in the trial group and 63.6% and 43.3% in the control group,respectively（P〈0.05）,there were no obvious adverse reactions expect some mild nausea,which could been tolerated.Conclusion NDP combined with radiotherapy can effectively treated esophageal cancer in aged patients.

关 键 词：奈达铂 放疗 老年食管癌 

分 类 号：R735.1[医药卫生—肿瘤]